Decision making for pancreatic resection in patients with intraductal papillary mucinous neoplasms

Table 1 Univariate predictors of invasive intraductal papillary mucinous neoplasms

Factors	Noninvasive	Invasive	t/χ2	P value
Gender
Male	12	24
Female	6	12	0.00	1.00
Age (yr)	60.00 ± 8.48	61.94 ± 7.76	-0.84	0.40
Size of lesion (mm)1
≤ 30	16	2
> 30	2	20	25.47	< 0.01
Type
Non-branch duct	10	36
Branch duct	8	0	18.78	< 0.01
Morphology of the lesion1
Unilocular cystic	4	0
Multiocular cystic	14	6
Cystic and solid	0	16	23.03	< 0.01
Septum
Yes	12	6
No	6	30	20.00	0.072
Solid appearance
Yes	1	26
No	17	10	21.33	< 0.01
Diameter of main pancreatic duct (mm)
≤ 8.25	18	20
> 8.25	0	16	11.36	< 0.01
Diameter of common bile duct (mm)
≤ 8.7	18	12
> 8.7	0	24	21.60	< 0.01

¹Not including main-duct intraductal papillary mucinous neoplasms.

Table 2 Univariate predictors of malignant intraductal papillary mucinous neoplasms

Factors	Benign	Malignant	t/χ2	P value
	(n = 16)	(n = 38)
Gender
Male	10	26
Female	6	12	0.18	0.67
Age (yr)	61.75 ± 7.22	61.29 ± 8.72	-0.18	0.85
Lumbodorsal pain
Yes	0	3
No	10	31	1.50	0.22
Jaundice
Yes	0	19
No	16	19	12.34	< 0.01
Direct bilirubin (μmol/L)
≤ 6.0	14	12
> 6.0	2	26	14.10	< 0.01
ALP (U/L)
≤ 115	13	12
> 115	3	26	9.26	0.02
γ-GT (U/L)
≤ 50	13	10
> 50	3	28	13.80	< 0.01
CA19-9 (U/mL)
≤ 37	14	8
> 37	2	30	20.59	< 0.01
CEA (ng/mL)
≤ 5	15	33
> 5	1	5	0.54	0.65

ALP: Alkaline phosphatase; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9.